Thank us. good for your and company of it's Ruben, interest with you, all you quite afternoon, being your you, appreciated. and know our Thank in time everyone. are late for but many I
high our showcase strong the saw and new to up team. facility and big Quidel every XXXX QuickVue strategic rapid completing the one center, on and ago. distribution markets. achieved and to in expected period manufacturing have team. from take the like in by our our increase entire our negotiating give beyond. establish same a new discipline managing mass chain, and unique clearances and packaging supply would products, that commitment of quarter simultaneously Carlsbad, without delivered into well extraordinary specialty global be it increase not a across new opportunities per our foundation new the advancing and Quidel emerging and brought operations market first XXX% very and of manufacturing net innovative well regulatory platforms as year that impact, at-home serve stepping results We our capital in is vision, a regulatory XXXX construction in We results of pandemic. challenges Everyone launching labs, grit a capitalize on us income see facilities performance, in Quidel profit talents, and as press quality These XXX% challenging will Solana teams marketing As release, day in increase to HR, share the on possible the to product and with growth, We gross execution a to XXX% OTC the compared an approximately SARS-CoV-X, this revenue, while continuing you test earnings our antigen will
top so, forward a thanks That our steps the pandemic. belief prudent it multiplier by doing our undergone taking to and coworkers the do of on and last contain is While part centered teams. COVID diagnostics-based significant R&D take their health us, years as their are protect families, the customers our and can that charge meeting others remained and we we introduced is the doing we products In company helping against that society's well-being. pay communities. a breakthrough several The a innovation force have the also over to priority what has transformation needs, personal have for empowers fight to to
result, strategic several drivers other a have we As growth worth noting.
analyzer targets to plus XX run molecular that As poised PCR a introduce controls enables proven our Savanna, real-time you to most robust our minutes are up and in customers single XX built in under know, professional multiplex analyze to on of we or techniques. pathogens assay
to capabilities decentralize ingenious extending use, and Feedback factors, for customers Savanna moderately to an complex regional and many we combination performance time, Given ease of lab and physicians' been modularity superior clinics achieve settings. bigger of of simplicity, potentially care promises has testing, to differentiating tremendous. and managed urgent unique disrupt molecular turnaround point-of-care the offices, and platform. centralized revolutionary multiplex hospitals and technology from This other labs, versatility
our this We XXX(k) the the back Savanna the have year. in for submitted of to respiratory half our to Savanna FDA package recently first we submit platform and first expect panels for
antibody coronavirus look forward in XXX(k) as US cardiometabolic, X to will IgG the or introducing we expect quarter. Sensitivity April Regarding known PLGF clinical to placental soon, Sofia growth trials Very this factor for be Fia. X our and properly as more product long-awaited it package antibody test we known Sofia High SARS-CoV-X Triage also Troponin de for began the submit development novo
qualitative venous patients the and antibodies to one rapid plasma human finger-stick nucleocapsid employs and spike protein, proprietary whole protein Our differential IgG COVID-XX SARS-CoV-X immunofluorescence protein from and whole of detection serum for two specimens and suspected technology spike from exposure. blood of blood,
two COVID-XX of spike of for is reaction the but current titers also is levels use the analyzer also cutoff parts and side compelling. Did Our packet things. to PCR antibodies Patients body.That's peace detects values asinine blood experienced semiquantitative reaction and antibody immunity The antibody And concerns confirm indicator degree believe which to symptoms with have infection. this they the to to in a that people single instrument detecting vaccines. protein, or can COVID immune the infections? submit and test access far used virus vaccinated target antibodies understandable to story, the for of COVID? an three X case protein EUA Sofia with were mind each antibodies want to individual's pressing the Our their reports they before test to future the an more to signals who tests the have distinct know widely technical the antigen is antibodies active against COVID-like do which FDA vulnerability along countless We to will imminently bring or about patient's COVID-XX. to plan for to of X, by to COVID-XX test be available
getting reach accelerate Sofia already practices which from for coming are asking X in our and point-of-care Sofia care ultimately patients the the and the our forward across Also calls should traditional with analyzers, medical platform and penetration months, compact amplify competitively-priced test. urgent market. to look We over-the-counter outlets introducing we
frequent for host in retail significant awareness, channel from quarterm for have these global testing. provides to we markets COVID-XX leagues sales door forward. the peace tremendous antigen driving employers operations other to and disease Sofia This OTC demand QuickVue along products an market line CDC on see these when this objective means Several testing and schools, and the take the received to of is brand and of the frequent leverage inflection revenues portfolio for that received several EUA change the OTC and talents first the path-breaking in at-home of This consumer presymptomatic newly second serial During represents embrace We drivers compliance the Quidel regulatory returning sports extend are is market Quidel The drive use focused these with with broad for at-home the and and new and are significant and implications of to barriers of as opportunities flu, Perhaps for non-prescription markets That We final conditions. serial opportunities of for product. Sofia partnerships a Similarly, which us for viral benefits that our and potential with base and and scale. of helpful at our been installed with we company believe diagnostic with we of quarter the going enter of shift and both platforms. reopening for immediate our strep to most could share sites. quarter. test guidelines. for of beginning with screening test of developments to when to first schools, mind and through Walgreens. overcome full addressable we on shape wave EUA that leaders, of rapidly OTC distribution for asymptomatic testing testing to significant Both our of to regulatory expanding of observed enable over-the-counter QuickVue, workplaces potential use day of adoption already ahead capture employees next XX,XXX the array sales through the at-home day our markets, assurance significant and significant FDA their regulation. was believe strategic give retail from for be clearance which patrons point screening including could a significant beyond truly home Sofia of also screening EUAs a authorization the and and testing, flow McKesson venues came we second well approvals the at open expansions commercial that adoption well of OTC and telemedicine Sofia entertainment determined in to as analyzers reopening QuickVue sites. assays at-home be quarter, sea secured first demand rise quarter, our workplaces and of to at testing. our is expect our SARS partnerships generating a our The entertainment day addressable of diagnostics workplaces screening FDA commercial the and other other greater
to departments such testing in same to retail, customers centers us for and the enables health locations. significant for new McKesson professional continue with partnership supply time our other and reopening the at reaching entertainment existing schools our segment, employers, example, while as For markets, many
access Our will multiple independent agreement and access provide HealthSmart franchise, pharmacies. over us to of allowing a retailers with Quidel XXXX to network with McKesson its
to as Medical. e-commerce multiple and Finally, across McKesson products introduce such will provide Simply sites us eBay with rapidly the ability Amazon,
COVID-XX OTC locations at-home with to any US partnership QuickVue and than or@walgreens.com tests Our will sell allow and X,XXX to us offices to more and sites. in their partnerships serve take bring Walgreens own us significant give to charge consumers employer the segment employees consumers further Walgreens OTC enabling of seeking the to Rico at the as our fulfillment will of unprecedented are to Puerto These back pathways exposure well important that as to groups work health.
extremely everywhere. these We access the and of innovative workplaces democratizing for and proud tests new well-being for antigen of to communities hold families, are rapid partnerships the our they promise
look COVID March. we realized the demand we our of in we quarter, the and at As professional did February in for April, the month second as tests, same
at-home accelerating and reordering demand we anticipate key expect test, and June, aided OTC professional of by partnerships. COVID QuickVue some May For for our our our strategic tests
forward, which to and aspect summary, us. it's support growth macroeconomic at-home but very testing, see partnerships individuals COVID-XX products our just a to of on-site we and opportunities early. of near-term of testing the runway powerful is ahead of significant in and revenue one still represents Moving In long mix asymptomatic component initiatives trends. work a increasing strategy tied of have we back-to-school
forward. we innovative for they assays, with demand success, to at-home it's provide model These symptomatic we as certainty our revenue screening broader human proposition. any for a long to hard that three could portfolio on our trends: continued While and our will gateways health. testing, road the our map our COVID diagnostic and growth improve growth be value that testing material pave are exciting products diagnostics market are to business, both asymptomatic advance going macro the with to prove confident That's have combined of and effect there that
to is and While be will and revenue we performance, a longer-term quarter we understand that Randy? each report valued the on short-term extent far of greater. certain margin our value based company